Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy.

Heumos, Simon; Dehn, Sandra; Bräutigam, Konstantin; Codrea, Marius C; Schürch, Christian M; Lauer, Ulrich M; Nahnsen, Sven; Schindler, Michael (2022). Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy. Cancer cell international, 22(1), p. 311. BioMed Central 10.1186/s12935-022-02710-y

[img]
Preview
Text
s12935-022-02710-y.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (4MB) | Preview

BACKGROUND

Immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized cancer therapy. However, therapeutic targeting of inhibitory T cell receptors such as PD-1 not only initiates a broad immune response against tumors, but also causes severe adverse effects. An ideal future stratified immunotherapy would interfere with cancer-specific cell surface receptors only.

METHODS

To identify such candidates, we profiled the surface receptors of the NCI-60 tumor cell panel via flow cytometry. The resulting surface receptor expression data were integrated into proteomic and transcriptomic NCI-60 datasets applying a sophisticated multiomics multiple co-inertia analysis (MCIA). This allowed us to identify surface profiles for skin, brain, colon, kidney, and bone marrow derived cell lines and cancer entity-specific cell surface receptor biomarkers for colon and renal cancer.

RESULTS

For colon cancer, identified biomarkers are CD15, CD104, CD324, CD326, CD49f, and for renal cancer, CD24, CD26, CD106 (VCAM1), EGFR, SSEA-3 (B3GALT5), SSEA-4 (TMCC1), TIM1 (HAVCR1), and TRA-1-60R (PODXL). Further data mining revealed that CD106 (VCAM1) in particular is a promising novel immunotherapeutic target for the treatment of renal cancer.

CONCLUSION

Altogether, our innovative multiomics analysis of the NCI-60 panel represents a highly valuable resource for uncovering surface receptors that could be further exploited for diagnostic and therapeutic purposes in the context of cancer immunotherapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Bräutigam, Konstantin

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1475-2867

Publisher:

BioMed Central

Language:

English

Submitter:

Pubmed Import

Date Deposited:

13 Oct 2022 15:10

Last Modified:

05 Dec 2022 16:26

Publisher DOI:

10.1186/s12935-022-02710-y

PubMed ID:

36221114

Uncontrolled Keywords:

FACS Flow cytometry Immunotherapy Multiomics NCI-60 Receptorome Theranostics cancer

BORIS DOI:

10.48350/173707

URI:

https://boris.unibe.ch/id/eprint/173707

Actions (login required)

Edit item Edit item
Provide Feedback